What is the duration of action of Vyvanse (lisdexamfetamine) and how long does its effect typically last?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Action of Vyvanse (Lisdexamfetamine)

Vyvanse provides 13-14 hours of therapeutic effect in clinical practice, making it the longest-acting ADHD stimulant available with once-daily morning dosing. 1, 2, 3

Pharmacokinetic Profile and Onset

  • Lisdexamfetamine is a prodrug that remains therapeutically inactive until enzymatic hydrolysis in the blood converts it to active d-amphetamine, with this rate-limited conversion occurring predominantly via red blood cell enzymes. 1, 3

  • The onset of action begins within 1.5-2 hours post-dose, with measurable clinical effects demonstrated as early as 1.5 hours in controlled laboratory school studies. 2, 4

  • Peak therapeutic effects occur approximately 3-4 hours after administration, with the prodrug design creating a smoother plasma concentration curve compared to immediate-release amphetamines. 3

Duration of Therapeutic Coverage

  • In children aged 6-12 years, efficacy is maintained for 13 hours post-dose, as demonstrated in rigorous laboratory school studies measuring ADHD symptoms at multiple time points throughout the day. 2, 3

  • In adults, the duration extends to 14 hours post-dose, providing coverage that extends late into the day for work and evening activities. 3, 5

  • This represents significantly longer coverage than other long-acting stimulants: extended-release mixed amphetamine salts provide 8-9 hours, while OROS-methylphenidate (Concerta) provides 10-12 hours. 6

Clinical Advantages of Extended Duration

  • Single morning dosing eliminates the need for in-school or workplace administration, addressing compliance issues, stigma concerns, and the logistical challenges of multiple daily doses. 1, 6

  • The prodrug design provides consistent therapeutic coverage throughout the entire school/work day and into evening hours for homework, after-school activities, and family interactions without requiring supplemental afternoon doses. 1

  • The extended duration prevents plasma concentration troughs during unstructured times (lunch, recess, bus rides home) that occur with shorter-acting formulations. 6

Comparison to Other Stimulant Durations

  • Immediate-release methylphenidate and dextroamphetamine: 4-6 hours, requiring 2-3 doses daily. 7

  • Older sustained-release formulations: 4-6 hours of clinical action, inadequate for full-day coverage. 6

  • Newer extended-release methylphenidate (Ritalin LA, Metadate CD): 8 hours of action. 6

  • Extended-release mixed amphetamine salts (Adderall XR): 8-9 hours. 6

  • OROS-methylphenidate (Concerta): 10-12 hours. 6

  • Lisdexamfetamine (Vyvanse): 13-14 hours, the longest available. 2, 3, 5

Common Pitfalls to Avoid

  • Do not assume all patients require the full 13-14 hour coverage—some patients may experience insomnia or appetite suppression extending too late into the evening, particularly if dosed after early morning. 6

  • Avoid dosing after mid-morning to minimize insomnia risk, as the 13-14 hour duration means effects will persist into late evening if taken too late. 6

  • Monitor for typical stimulant adverse effects including decreased appetite (most common), insomnia, headache, and irritability, which are generally mild to moderate and transient. 2, 8, 3

References

Guideline

Pharmacokinetics of Lisdexamfetamine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry.

Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent, 2010

Guideline

Methylphenidate Extended-Release Formulations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.